middl
east
respiratori
syndrom
coronaviru
merscov
infect
least
patient
caus
death
sinc
first
appear
yet
neither
pathogenspecif
therapeut
approv
vaccin
avail
address
need
develop
subunit
recombin
protein
vaccin
compris
residu
merscov
spike
protein
receptorbind
domain
rbd
formul
addavax
adjuv
induc
signific
neutral
antibodi
respons
protect
merscov
challeng
vaccin
anim
prepar
manufactur
firstinhuman
test
vaccin
develop
process
stabli
produc
recombin
mer
protein
chines
hamster
ovari
cho
cell
accomplish
transfect
adher
dihydrofol
reductasedefici
cho
cell
line
adcho
plasmid
encod
fuse
human
igg
fc
fragment
demonstr
signal
peptidedirect
secret
recombin
protein
extracellular
milieu
use
gradual
increas
methotrex
mtx
concentr
lm
increas
protein
yield
factor
adchoexpress
recombin
protein
demonstr
function
bind
specif
ident
protein
transient
transfect
cell
addit
dipeptidyl
transgen
mice
vaccin
addavaxadjuv
could
produc
neutral
antibodi
merscov
surviv
least
day
challeng
live
merscov
evid
immunolog
toxic
eosinophil
immun
enhanc
prepar
larg
scalemanufactur
vaccin
antigen
develop
highyield
monoclon
suspens
cho
cell
line
death
confirm
case
sinc
origin
appear
arabian
peninsula
middl
east
respiratori
syndrom
mer
coronaviru
merscov
emerg
import
global
pathogen
potenti
pandem
threat
remain
critic
need
vaccin
target
merscov
newli
establish
coalit
epidem
prepared
innov
cepi
design
research
develop
merscov
vaccin
global
prioriti
recent
phase
studi
dnabas
vaccin
merscov
show
vaccin
volunt
gener
antibodi
mer
cov
howev
date
licens
dna
vaccin
human
due
part
question
longterm
safeti
abil
induc
high
titer
protect
neutral
antibodi
rel
recombin
proteinbas
vaccin
lead
candid
proteinbas
vaccin
receptorbind
domain
rbd
merscov
spike
protein
merscov
rbd
play
essenti
role
host
receptor
bind
membran
fusion
cell
entri
thu
make
ideal
vaccin
target
moreov
focus
rbd
compon
rather
fulllength
protein
reduc
likelihood
eosinophilicor
antibodydepend
immun
enhanc
express
purifi
recombin
fusion
protein
human
fc
fragment
addavax
adjuv
rbd
residu
merscov
shown
elicit
high
neutral
antibodi
titer
mice
rabbit
antibodi
display
potent
neutral
activ
almost
human
camel
merscov
strain
includ
amino
acid
mutat
rbd
region
spike
protein
complementari
approach
recombin
rbd
mutant
repres
differ
human
camel
viru
isol
abl
elicit
broadspectrum
neutral
antibodi
wide
rang
human
camel
merscov
strain
antibodi
rbd
abl
block
bind
rbd
merscov
cellular
receptor
thu
block
viral
entri
permiss
human
cell
importantli
recent
studi
found
neutral
antibodi
inde
associ
protect
vaccin
mice
mice
found
immun
lethal
merscov
challeng
although
vaccin
antigen
produc
small
laboratori
scale
transient
cell
system
littl
effort
put
forth
develop
scale
merscov
rbd
suitabl
futur
vaccin
manufactur
therefor
engin
stabl
cho
cell
line
suitabl
produc
merscov
protein
vaccin
antigen
codonoptim
dna
sequenc
encod
human
igg
fcfuse
signal
peptid
resid
nterminu
synthes
clone
use
xbai
noti
restrict
site
genescript
sequenc
encod
signal
peptid
deriv
igk
light
chain
igk
human
serum
albumin
sa
azurocidin
azu
incorpor
mer
touchdown
pcr
ultram
oligom
tabl
supp
tabl
pcr
product
gel
purifi
use
qiaquick
pcr
purif
kit
qiagen
subsequ
clone
poptivectopo
vector
invitrogen
follow
escherichia
coli
transform
ampicillinresist
transform
select
lb
agar
plate
contain
lgml
ampicillin
subsequ
grown
lb
broth
plasmid
dna
prepar
isol
coloni
sequenc
construct
express
plasmid
signal
peptid
digest
xbai
noti
restrict
enzym
gene
cassett
gel
purifi
express
plasmid
poptivec
digest
enzym
gel
purifi
follow
ligat
dna
ligas
adher
dihydrofol
reductas
dhfr
defici
cho
cell
adcho
atcc
tm
chodhfr
cultur
iscov
modifi
dulbecco
medium
imdm
gibco
supplement
mm
lglutamin
gibco
fetal
bovin
serum
fb
gibco
mm
sodium
mm
thymidin
ht
gibco
establish
adcho
cell
line
x
cell
transfect
lg
plasmid
dna
differ
signal
peptid
use
lipofectamin
invitrogen
accord
manufactur
instruct
plasmid
dna
linear
ahdi
prior
transfect
stabl
transfect
select
cultur
select
medium
medium
previous
describ
without
ht
supplement
cell
passag
everi
day
reach
maximum
cell
densiti
viabl
cell
per
ml
split
ratio
investig
effect
differ
signal
peptid
protein
express
condit
medium
transfect
collect
quantit
analysi
gene
amplif
transfect
adcho
cell
grown
confluenc
day
select
medium
supplement
mtx
concentr
mtx
increas
gradual
passag
day
per
passag
adcho
cell
nm
nm
nm
nm
nm
nm
nm
nm
nm
nm
recombin
mer
load
onto
hitrap
proteina
hp
column
ge
flow
rate
mlmin
column
wash
pb
ph
amesco
column
volum
cv
elut
cv
elut
buffer
mm
citric
buffer
ph
follow
cv
elut
buffer
elut
fraction
ml
collect
tube
contain
ml
trishcl
ph
elev
ph
elut
protein
ph
sdspage
western
blot
analysi
perform
rabbitantimerscov
rbd
rabbitantibovin
fab
sigma
antibodi
identifi
protein
elut
fraction
peak
fraction
contain
mer
protein
pool
concentr
mgml
amicon
centrifug
filter
unit
mwco
kda
bufferexchang
mm
trishcl
mm
nacl
ph
protein
secondari
structur
predict
circular
dichroism
cd
spectra
sampl
cd
experi
prepar
mm
citrat
phosphat
concentr
mgml
cd
spectra
record
jasco
spectrophotomet
scan
nm
nm
nmmin
bandwidth
nm
respons
time
experi
perform
use
one
quartz
cuvett
path
length
cm
keep
constant
temperatur
averag
valu
determin
five
scan
spectrum
match
buffer
alon
sampl
serv
control
secondari
structur
predict
use
cdpro
softwar
compar
three
refer
set
use
two
data
fit
program
contin
cdsstr
realtim
protein
melt
experi
perform
use
protein
thermal
shift
tm
dye
thermo
fisher
scientif
appli
biosystem
viia
realtim
pcr
system
thermo
fisher
scientif
yield
fluoresc
tabl
overview
test
signal
peptid
adcho
express
system
signal
peptid
signal
peptid
sequenc
ref
profil
specif
purifi
mer
evalu
ptm
purifi
protein
treat
peptidenglycosidas
f
pngasef
oglycosidas
neuraminidas
nondenatur
form
subsequ
analyz
gel
electrophoresi
coip
assay
carri
analyz
interact
adchoexpress
mer
human
receptor
cell
lysat
use
mer
express
cell
posit
control
sarscov
rbdfc
neg
control
cell
lysat
ml
ml
lysi
buffer
contain
ndecyldmaltopyranosidephosphatebuff
salin
sarscov
rbdspecif
mab
antisarsrbd
lgml
flow
cytometri
analysi
carri
quantifi
bind
merscov
rbd
cell
cell
incub
lgml
express
either
adcho
cell
cell
min
room
temperatur
follow
addit
fitclabel
antihuman
igg
antibodi
abcam
min
cell
analyz
flow
cytometri
detect
bind
merscov
rbd
protein
elisa
plate
precoat
overnight
lgml
purifi
protein
express
either
cell
adcho
cell
block
fatfre
milk
h
serial
dilut
protein
histag
llwell
ad
plate
incub
h
follow
four
wash
pb
pbst
subsequ
plate
incub
mous
antihi
primari
antibodi
sigma
h
four
wash
pbst
horseradish
peroxidas
hrp
conjug
antimous
igg
antibodi
ge
healthcar
ad
well
incub
min
final
plate
wash
pbst
bind
visual
ad
colorogen
substrat
tetramethylbenzidin
tmb
sigma
reaction
stop
min
ad
n
h
absorb
nm
measur
elisa
plate
reader
tecan
detect
bind
merscov
rbd
rbdspecif
neutral
mab
perform
follow
protocol
similar
describ
except
plate
precoat
lgml
purifi
protein
follow
sequenti
incub
serial
dilut
mous
mab
human
mab
hrpconjug
antimous
igg
mous
mab
ge
healthcar
antihumanfab
human
fabmab
sigma
antibodi
bind
denatur
merscov
rbd
aforement
rbdspecif
neutral
mab
rbdimmun
mous
sera
test
elisa
describ
except
plate
precoat
lgml
protein
treat
dithiothreitol
dtt
mm
sigma
h
follow
incub
iodoacetamid
mm
sigma
h
stop
reaction
three
wash
elisa
carri
describ
vitro
vivo
studi
requir
usag
infecti
merscov
strain
conduct
within
approv
biosafeti
level
anim
laboratori
galveston
nation
laboratori
strictli
follow
approv
notificationofusag
nou
anim
protocol
guidelin
regul
nation
institut
health
aaalac
proofofprincip
studi
confirm
adchoexpress
mer
effect
safe
vaccin
two
group
five
agematch
transgen
tg
mice
immun
twice
four
week
apart
via
intramuscular
im
rout
either
lg
mer
formul
addavax
invivogen
pbsaddavax
control
immun
protocol
select
optim
merscov
rbd
protein
addavax
adjuv
chosen
promot
rbdfc
protein
gener
highest
neutral
antibodi
among
sever
adjuv
test
previou
studi
serum
specimen
collect
day
second
immun
retroorbit
bleed
rout
determin
prospect
capac
neutral
infecti
merscov
use
standard
vero
microneutr
test
immun
mice
subsequ
challeng
intranas
lethal
dose
ld
tcid
merscov
strain
gift
heinz
feldmann
nih
hamilton
mt
ron
fouchier
erasmu
medic
center
rotterdam
netherland
follow
daili
monitor
onset
clinic
manifest
eg
weight
loss
clinic
manifest
mortal
three
mice
group
euthan
day
postinfect
pi
assess
lung
viral
load
vero
infect
assay
quantit
q
pcr
analysi
target
upe
gene
merscov
quantifi
infecti
viru
viral
rna
respect
addit
deparaffin
lung
tissu
hematoxylinandeosin
h
e
stain
routin
histopatholog
evalu
describ
continu
monitor
remain
two
mice
group
overal
wellb
total
week
termin
experi
methodolog
requir
assess
immunogen
neutral
antibodi
titer
efficaci
mer
previous
report
supplementari
method
suspens
cho
cho
gibco
hereinaft
term
suscho
cell
cultur
cd
medium
gibco
supplement
mm
lglutamin
gibco
pluron
prior
transfect
transfect
perform
combin
lg
ahdilinear
plasmid
freestyl
tm
max
reagent
invitrogen
ml
optipro
sfm
incub
room
temperatur
min
follow
dropwis
addit
cell
ml
cd
cultur
medium
nonselect
accord
manufactur
instruct
h
cell
transfer
select
medium
cd
opticho
invitrogen
supplement
mm
lglutamin
pluron
gibco
cultiv
cell
viabil
reach
select
stabli
transfect
suscho
cell
underw
dna
amplif
gradual
increas
mtx
concentr
nm
select
medium
suspens
cultur
flask
maintain
humidifi
incub
co
shaker
constant
rotat
rate
rpm
lm
mtxadapt
suscho
cell
pool
serumfre
medium
use
singlecel
clone
limit
dilut
cellswel
clone
perform
plate
falcon
ubottom
untreat
util
clone
medium
compos
hybridoma
sfm
clonacel
condit
media
supplement
cho
acf
supplement
clonacel
co
approxim
day
condit
medium
well
activ
grow
singl
coloni
assay
elisa
follow
mixtur
condit
medium
coat
buffer
ad
elisa
plate
thermo
fisher
scientif
incub
overnight
wash
plate
pbst
rabbit
antihuman
igg
use
detect
protein
follow
biotinyl
goat
antirabbit
antibodi
streptavidin
hrp
tetramethylbenzidin
kpl
inc
vwr
ad
reaction
stop
hcl
elisa
plate
read
epoch
micropl
spectrophotomet
biotek
instrument
inc
nm
clone
gave
high
absorb
read
propag
plate
util
cd
opticho
medium
mm
lglutamin
pluron
condit
medium
plate
also
screen
elisa
confirm
highest
express
clone
select
expand
passag
shake
flask
co
air
orbit
shaker
platform
rotat
rpm
clonal
cell
line
heterogen
suscho
cell
pool
collect
daili
day
count
use
acridin
orang
ao
propidium
iodid
pi
nuclear
stain
dye
nexcelom
bioscienc
enter
live
cell
dead
cell
respect
condit
medium
time
point
analyz
sdspage
protein
concentr
estim
densitometri
compar
protein
standard
use
chemidoc
tm
imag
system
biorad
statist
signific
calcul
student
test
use
graphpad
prism
statist
softwar
indic
p
previou
studi
human
igg
fcfuse
fragment
merscov
protein
genbank
hereinaft
term
mer
alreadi
express
transient
transfect
cell
howev
establish
stabli
express
cell
clone
transfect
adher
cho
adcho
poptivec
construct
contain
intern
ribosom
entri
site
ire
driven
dhfr
gene
select
copi
number
amplif
well
mer
gene
fusion
signal
peptid
ad
ntermin
end
gene
order
drive
secret
cultur
medium
fig
addit
gradual
increas
methotrex
mtx
cultur
medium
transfect
cell
result
bind
inactiv
dihydrofol
reductas
dhfr
activ
transfect
adcho
cell
compens
reduc
dhfr
activ
increas
dhfr
copi
number
genom
overcom
inhibit
mtx
sinc
mer
fusion
gene
integr
genet
locu
dhfr
gene
gene
amplifi
well
lead
increas
product
protein
cours
develop
adcho
cell
line
express
protein
optim
purif
protocol
use
hitrap
proteina
hp
perform
purif
chromatogram
two
protein
peak
observ
elut
step
fig
denatur
sdspage
western
blot
analysi
antimersrbdspecif
antibodi
confirm
second
peak
fragment
fig
analysi
use
nondenatur
sdspage
western
blot
rbantibovin
fab
antibodi
show
first
peak
mainli
contamin
bovin
igg
fig
origin
fetal
bovin
serum
fb
supplement
cultur
medium
estim
rel
product
adcho
cell
measur
ratio
area
first
peak
second
peak
differ
signal
peptid
shown
result
differ
express
level
cho
cell
system
therefor
transfect
adcho
cell
linear
mer
express
plasmid
four
differ
signal
peptid
nterminu
peptid
deriv
interleukin
igk
light
chain
igk
human
serum
albumin
sa
azurocidin
azu
condit
media
confluent
monolay
transfect
cell
line
collect
follow
protein
purif
use
protein
establish
yield
estim
rel
product
studi
found
adcho
cell
signal
peptid
deriv
show
secret
cell
signal
peptid
fig
elev
express
level
achiev
gradual
increas
mtx
concentr
cell
passag
nm
lm
condit
medium
transfect
adcho
cell
collect
dna
amplif
process
follow
protein
purif
use
protein
estim
rel
product
fig
observ
expect
correl
express
increas
resist
higher
level
mtx
compar
adcho
cell
nm
mtx
express
increas
presenc
lm
mtx
fig
purifi
protein
analyz
circular
dichroism
cd
spectroscopi
merscov
consist
mainli
betasheet
loop
structur
limit
helic
fig
secondari
structur
protein
start
unfold
thermal
melt
analysi
mer
two
endotherm
transit
fig
comparison
mer
express
cell
adcho
cell
carri
use
differ
page
analys
protein
appear
ident
follow
reduc
nonreduc
sdspage
nativ
page
ief
gel
adchoexpress
mer
lower
isoelectr
point
pi
compar
protein
express
cell
pi
fig
remov
nlink
glycan
molecular
size
mer
slightli
smaller
nlink
glycosyl
form
fig
chang
molecular
weight
observ
olink
deglycosyl
desialyl
reduc
sdspage
enzymat
treatment
affect
dimer
mer
determin
nonreduc
sdspage
high
pi
isom
exhibit
lower
shift
pi
pi
electrophoret
mobil
nlink
deglycosyl
chang
band
pattern
protein
seen
treatment
oglycosidas
remov
sialic
acid
neuraminidas
treatment
isom
shift
pi
higher
fig
three
assay
includ
coimmunoprecipit
coip
flow
cytometri
elisa
perform
detect
bind
merscov
rbd
receptor
coip
demonstr
similar
mer
protein
rbd
protein
express
adcho
bound
strongli
cell
two
clear
band
identifi
immunoprecipit
mixtur
cell
lysat
band
recogn
antibodi
antimersrbd
antibodi
contrast
one
band
identifi
cell
protein
sampl
reactiv
either
antibodi
antimersrbd
antibodi
antibodi
expect
sarscov
rbdfc
protein
recogn
sarscov
rbdspecif
mab
fig
flow
cytometri
analysi
quantifi
bind
merscov
rbd
protein
receptor
cell
result
show
similar
strong
bind
mer
protein
adcho
sarscov
rbdfc
control
fig
elisa
analysi
demonstr
dosedepend
bind
merscov
rbd
protein
protein
bind
observ
hfc
control
fig
antigen
merscov
rbd
protein
carri
use
elisa
test
bind
rbdspecif
neutral
antibodi
recogn
epitop
rbd
residu
demonstr
strong
activ
block
receptor
bind
neutral
merscov
infect
similar
protein
express
rbd
protein
express
adcho
bound
strongli
mous
mab
human
mab
dosedepend
manner
fig
confirm
antigen
mab
bound
strongli
nondenatur
dtt
protein
express
adcho
significantli
reduc
affin
rbd
protein
treat
dtt
reduc
agent
cleav
disulfid
bond
rbd
thu
disrupt
protein
nativ
conform
fig
result
demonstr
neutral
mab
recogn
conform
structur
merscov
rbd
transgen
mice
express
human
receptor
wellcharacter
anim
model
evalu
efficaci
vaccin
candid
merscov
infect
diseas
immunogen
mer
subunit
vaccin
verifi
mice
immun
sera
obtain
immun
mice
test
elisa
bind
denatur
nondenatur
protein
subject
vero
microneutr
assay
quantifi
capac
neutral
infecti
merscov
evalu
protect
efficaci
viral
infect
viral
load
histopatholog
lung
three
mice
immun
control
group
measur
day
lethal
challeng
ld
merscov
remain
two
mice
group
monitor
morbid
weight
loss
mortal
determin
vaccin
formul
would
suffici
protect
diseas
lethal
caus
merscov
infect
mer
induc
high
titer
rbdspecif
igg
antibodi
react
strongli
nondenatur
protein
nevertheless
rbdspecif
antibodi
significantli
reduc
activ
treat
dtt
fig
suggest
rbd
vaccineinduc
antibodi
respons
inde
direct
toward
one
conform
epitop
mice
immun
pbsaddavax
uniformli
fail
elicit
detect
neutral
antibodi
howev
immun
mer
consist
produc
readili
detect
titer
neutral
antibodi
rang
neutral
titer
nt
nt
nt
respect
tabl
consist
readili
detect
neutral
antibodi
mer
mice
fulli
protect
viral
infect
diseas
evidenc
absenc
recover
infecti
viru
neglig
focal
inflammatori
respons
supp
fig
within
infect
lung
day
postinfect
dpi
importantli
remain
two
immun
mice
suffer
signific
morbid
weight
loss
surviv
dpi
experi
termin
contrast
pulmonari
infecti
virus
albeit
low
titer
detect
three
unimmun
control
averag
tcid
g
merscov
recov
dpi
accompani
mild
inflammatori
respons
remain
two
control
mice
suffer
profound
weight
loss
prior
succumb
infect
dpi
taken
togeth
result
proofofprincipl
pilot
studi
indic
immunogen
merscov
also
efficaci
safeti
protect
mice
lethal
challeng
merscov
similar
adcho
cell
develop
describ
earlier
dna
copi
number
stabli
transfect
suspens
cho
dhfrcell
amplifi
gradual
exposur
increas
mtx
concentr
lm
result
heterogen
suscho
cell
pool
subsequ
clone
limit
dilut
obtain
monoclon
cell
popul
elisa
analysi
perform
supernat
individu
clone
lead
identif
clone
highest
express
clone
compar
growth
curv
clone
heterogen
nonclon
suscho
cell
discov
clone
heterogen
suscho
cell
reach
maximum
growth
seventh
day
viabl
cell
count
cellsml
cellsml
respect
fig
quantit
analysi
use
sdspage
determin
supernat
clone
express
approxim
mgl
mer
heterogen
nonclon
cell
pool
express
mgl
tabl
supp
fig
seventh
day
merscov
rbd
subunit
fragment
identifi
critic
neutral
receptorbind
fragment
ideal
candid
develop
effect
merscov
recombin
protein
vaccin
aim
optim
express
purif
condit
suitabl
pilot
scale
product
rbd
vaccin
candid
initi
escherichia
coli
bacteria
pichia
pastori
yeast
express
system
prove
well
suit
recombin
vaccin
product
low
product
cost
howev
data
show
e
coli
could
produc
solubl
mer
yeast
cell
could
overexpress
mer
thu
two
system
consid
suitabl
advanc
mer
vaccin
candid
process
develop
scale
product
see
supplementari
inform
detail
previou
report
mer
fcfuse
express
transient
transfect
cell
howev
transient
transfect
cell
line
may
give
low
protein
yield
potenti
lose
product
abil
time
continu
express
recombin
protein
unlik
transient
transfect
dna
integr
cell
longterm
stabl
transfect
despit
fact
develop
stabli
express
cell
line
labori
timeconsum
product
stabl
cell
line
scale
easili
would
suitabl
use
manufactur
process
henc
gener
stabli
transfect
adcho
cell
line
transfect
mtxdriven
poptivec
cell
produc
recombin
mer
protein
fcfuse
protein
first
construct
potenti
candid
aid
therapi
fda
approv
fcfusion
vaccin
vaccin
develop
use
fcfusion
protein
activ
ongo
number
studi
initi
develop
vaccin
ebola
hiv
influenza
well
tuberculosi
note
advers
side
effect
vaccin
like
limit
biotherapeut
fc
fusion
repeatedli
shown
safe
biocompat
human
current
commerci
therapeut
use
fc
domain
human
although
option
iga
igm
also
current
explor
furthermor
fc
domain
known
increas
plasma
halflif
simplifi
purif
process
purif
perform
use
protein
sepharos
column
remov
impur
cultur
medium
bovin
igg
origin
fb
cultur
medium
constant
amount
use
standard
gaug
express
level
protein
estim
method
allow
us
select
suitabl
signal
peptid
evalu
effect
mtxinduc
dna
amplif
process
sinc
poptivec
plasmid
signal
peptid
four
differ
signal
peptid
subsequ
test
nterminu
sequenc
drive
secret
protein
lead
identif
signal
peptid
suitabl
signal
sequenc
although
signal
peptid
deriv
human
sa
human
azu
report
improv
product
rate
adcho
system
yield
hand
lower
signal
peptid
stabl
highli
product
cell
pool
isol
gradual
increas
mtx
concentr
cultur
analysi
rel
product
adcho
cell
indic
increas
media
proport
mtx
concentr
medium
reach
plateau
lm
mtx
biophys
biochem
character
mer
protein
reveal
stabl
temperatur
first
major
unfold
event
anoth
unfold
event
occur
could
result
destabil
bond
fc
domain
recombin
protein
chang
molecular
weight
observ
remov
olink
glycan
mer
suggest
olink
glycosyl
protein
neuraminidas
treatment
recombin
protein
band
pattern
show
fewer
band
pi
shift
suggest
sialic
acid
might
contribut
charg
protein
interestingli
although
complex
multipl
protein
band
greatli
reduc
glycosidas
sialidas
treatment
pattern
repres
charg
heterogen
remain
suggest
exist
addit
ptm
recombin
mer
protein
due
charg
differ
adchoand
protein
evalu
function
antigen
target
protein
function
studi
includ
coip
assay
flow
cytometri
analys
elisa
bind
assay
confirm
adchoexpress
mer
protein
maintain
function
equal
express
cell
bind
receptor
merscov
show
dosedepend
bind
solubl
protein
addit
mer
express
either
adcho
demonstr
similar
dosedepend
bind
rbdspecif
neutral
antibodi
indic
protein
could
maintain
suffici
antigen
investig
protect
efficaci
adchoexpress
protein
vaccin
protect
merscov
infect
establish
transgen
mous
model
express
formul
protein
addavax
vaccin
anim
could
produc
neutral
antibodi
surviv
live
viral
challeng
day
taken
togeth
confirm
absenc
function
antigen
immunogen
differ
adchoand
mer
protein
moreov
mous
vaccin
rbd
subunit
vaccin
appear
elicit
eosinophil
antibodydepend
immun
enhanc
although
verifi
adchoexpress
mer
protein
effect
vaccin
merscov
infect
use
fb
growth
medium
prove
unsuit
human
vaccin
antigen
safeti
complianc
futur
regulatori
requir
therefor
develop
stabli
transfect
suspens
cho
cell
line
serumfre
medium
adcho
cell
develop
process
describ
becam
foundat
establish
serumfre
suspens
cho
cell
line
subsequ
transfect
poptivec
express
plasmid
signal
peptid
suscho
cell
carri
dna
amplif
heterogen
cell
pool
adapt
lm
mtx
isol
clone
highest
express
clone
twocycl
screen
process
shake
flask
growth
clone
slightli
slower
heterogen
cell
pool
express
mer
protein
heterogen
cell
pool
typic
highli
product
cell
clone
lower
growth
rate
sinc
signific
portion
resourc
use
express
recombin
protein
addit
experi
transgen
mice
nonhuman
primat
model
need
determin
immunogen
mer
protein
produc
suscho
envis
proper
product
process
recombin
protein
scale
manufactur
formul
stockpil
effici
countermeasur
futur
merscov
outbreak
tabl
express
heterogen
nonclon
suscho
cell
pool
monoclon
clone
protein
concentr
mg
protein
per
liter
cultur
supernat
determin
sdspage
gel
analysi
supp
fig
